Wedbush Securities Inc. Cuts Holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Posted by on Apr 19th, 2023

Wedbush Securities Inc. reduced its stake in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 56.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,068 shares of the biopharmaceutical company’s stock after selling 2,650 shares during the period. Wedbush Securities Inc.’s holdings in Horizon Therapeutics Public were worth $235,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. bought a new stake in Horizon Therapeutics Public during the fourth quarter worth about $28,000. Allworth Financial LP lifted its position in Horizon Therapeutics Public by 936.7% in the 3rd quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 562 shares during the last quarter. CI Investments Inc. boosted its stake in Horizon Therapeutics Public by 75.9% in the third quarter. CI Investments Inc. now owns 628 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 271 shares in the last quarter. Samalin Investment Counsel LLC bought a new position in Horizon Therapeutics Public during the first quarter valued at approximately $41,000. Finally, TD Capital Management LLC bought a new position in Horizon Therapeutics Public during the third quarter valued at approximately $50,000. 91.01% of the stock is currently owned by hedge funds and other institutional investors.

Horizon Therapeutics Public Stock Performance

Shares of NASDAQ:HZNP opened at $111.90 on Wednesday. The company has a current ratio of 3.85, a quick ratio of 3.67 and a debt-to-equity ratio of 0.50. The company has a market cap of $25.56 billion, a price-to-earnings ratio of 50.18, a price-to-earnings-growth ratio of 4.20 and a beta of 1.13. Horizon Therapeutics Public Limited has a 12 month low of $57.84 and a 12 month high of $117.49. The company has a 50-day moving average price of $109.58 and a 200-day moving average price of $98.10.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.12. The firm had revenue of $942.03 million for the quarter, compared to analyst estimates of $922.95 million. Horizon Therapeutics Public had a return on equity of 23.04% and a net margin of 14.37%. The business’s quarterly revenue was down 7.1% compared to the same quarter last year. During the same period last year, the company earned $1.41 EPS. As a group, equities analysts anticipate that Horizon Therapeutics Public Limited will post 5.31 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Horizon Therapeutics Public in a research note on Wednesday. They issued a “buy” rating for the company. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Horizon Therapeutics Public currently has an average rating of “Hold” and a consensus price target of $111.42.

Horizon Therapeutics Public Company Profile

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Read More

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.